| In EUR millions | 2006 | 2007 | Change 2007/2006 | Change 2007/proforma 2006* at constant USD |
| First quarter | 18.3 | 21.2 | + 15.6 % | + 12.1 % |
| Second quarter | 16.3 | 20.6 | + 26.4 % | + 15.8 % |
| Third quarter | 15.1 | 18.3 | + 21.7 % | + 12.2 % |
| 9 months | 49.7 | 60.1 | + 21.0 % | + 13.4 % |
* With the integration of Hammer Pharma from January 1, 2006 and HP Botanicals from April 1, 2006
Naturex continued to enjoy sustained growth over the third quarter of 2007, posting revenues of EUR 18.3 million, up 21.7 %.
Revenues for the first nine months of the year stood at EUR 60.1 million, up 21.0 %. Proforma growth stood at 13.4% at constant USD rates and 7.7% at current USD rates.
Accordingly, Naturex's activity over the first nine months of the year is in with its development plan as the Group pursues its aggressive commercial strategy against a buoyant market backdrop.
Naturex will report its 2007 full-year revenues on January 28, 2008.
If you would like to receive free financial information about Naturex by e-mail, contact: www.kaparcafinance.com
NATUREX has been listed since October 1996
Eurolist by Euronext Paris, segment B, ISIN: FR0000054694, Reuters NATU.LN. Bloomberg NTRX
Contacts
|
NATUREX Jacques Dikansky – Président Directeur Général Tél. : +33 4 90 23 96 89 /j.dikansky@naturex.com Thierry Lambert – Directeur Général Adjoint Tél. : +33 4 90 23 96 89 / t.lambert@naturex.com |
ACTUS Agnès Gilbert – Relations presse Tél. : +33 1 53 67 36 33 / agilbert@actus.fr KAPARCA FINANCE Laurence Marquézy – Relations investisseurs Tél. : +33 1 72 74 82 23 / lmarquezy@kaparcafinance.com |